IDEXX Laboratories, Inc. (IDXX) Free Cash Flow (FCF): $1.05B
The free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX) is $1.05B. It is above its 12-month average by 13.79% ($925.74M).
IDXX Free Cash Flow (FCF) Chart
IDXX Average Free Cash Flow (FCF) Chart
IDXX Current vs Average Free Cash Flow (FCF) Chart
IDXX Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$1.05B
FREE CASH FLOW (FCF) AVG TTM
$925.74M
FREE CASH FLOW (FCF) AVG 3Y
$754.62M
FREE CASH FLOW (FCF) AVG 5Y
$699.15M
FREE CASH FLOW (FCF) AVG 10Y
$497.80M
FREE CASH FLOW (FCF) AVG 15Y
$389.97M
FREE CASH FLOW (FCF) AVG 20Y
$314.69M
CURRENT VS TTM AVG
+13.79%
CURRENT VS 3Y AVG
+39.59%
CURRENT VS 5Y AVG
+50.67%
CURRENT VS 10Y AVG
+111.61%
CURRENT VS 15Y AVG
+170.12%
CURRENT VS 20Y AVG
+234.74%
FCF Analysis
Free Cash Flow (TTM)
$1.05B
FCF Yield
2.31%
Price/FCF
43.3
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
IDEXX Laboratories, Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The free cash flow (FCF) for IDXX stock is $1.05B.
- What is the TTM average free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average free cash flow (FCF) for IDXX stock is $925.74M.
- What is the 3Y average free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average free cash flow (FCF) for IDXX stock is $754.62M.
- What is the 5Y average free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average free cash flow (FCF) for IDXX stock is $699.15M.
- What is the 10Y average free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average free cash flow (FCF) for IDXX stock is $497.80M.
- What is the 15Y average free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average free cash flow (FCF) for IDXX stock is $389.97M.
- What is the 20Y average free cash flow (FCF) for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average free cash flow (FCF) for IDXX stock is $314.69M.
IDEXX Laboratories, Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $1.05B |
| 2024-12-31 | $798.08M |
| 2023-12-31 | $772.88M |
| 2022-12-31 | $394.15M |
| 2021-12-31 | $636.00M |
| 2020-12-31 | $540.44M |
| 2019-12-31 | $303.93M |
| 2018-12-31 | $277.15M |
| 2017-12-31 | $296.57M |
| 2016-12-31 | $269.78M |
| 2015-12-31 | $133.44M |
| 2014-12-31 | $175.15M |
| 2013-12-31 | $167.36M |
| 2012-12-31 | $161.23M |
| 2011-12-31 | $120.48M |
| 2010-12-31 | $139.53M |
| 2009-12-31 | $115.88M |
| 2008-12-31 | $53.37M |
| 2007-12-31 | $68.88M |
| 2006-12-31 | $38.47M |
| 2005-12-31 | $92.35M |
| 2004-12-31 | $63.67M |
| 2003-12-31 | $100.26M |
| 2002-12-31 | $88.17M |
| 2001-12-31 | $28.98M |
| 2000-12-31 | $12.72M |
| 1999-12-31 | $40.20M |
| 1998-12-31 | $-2.00M |
| 1997-12-31 | $-22.00M |
| 1996-12-31 | $-3.80M |
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky